The Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

About this Study

The purpose of this research study is to compare the effects and safety of the study drug, MOR00208, given with bendamustine (BEN) to another treatment combination, rituximab (RTX) in combination with BEN to find out which combination is better for treating DLBCL.

Sponsor Protocol ID:MOR208C204
IRB Number:2018-0111
Closed for Enrollment
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria

  1. Age ≥18 years. 

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Lisa Goins-Freeman
Phone Number: 601-496-9600
Email: efreeman2@umc.edu
Principal Investigator:Elkins, Stephanie L, M.D.
How to participate in our Clinical Trials